Efficacy of nivolumab/ipilimumab in patients with initial or late progression with nivolumab: Updated analysis of a tailored approach in advanced renal cell carcinoma (TITAN-RCC).

Marc-Oliver Grimm,Emilio Esteban,Philippe Barthélémy,M. Schmidinger,Jonas Busch,Begoña P. Valderrama,Marc Schmitz,Ulrike Schumacher,Gustavo B. Baretton,Ignacio Duran,Guillermo Velasco,Frank Priou,Pablo Maroto-Rey,Giovanni Schinzari,Laurence Albiges

Efficacy of nivolumab/ipilimumab in patients with initial or late progression with nivolumab: Updated analysis of a tailored approach in advanced renal cell carcinoma (TITAN-RCC).

2021

Marc-Oliver Grimm
Emilio Esteban
Philippe Barthélémy
M. Schmidinger
Jonas Busch
Begoña P. Valderrama
Marc Schmitz
Ulrike Schumacher
Gustavo B. Baretton
Ignacio Duran
Guillermo Velasco
Frank Priou
Pablo Maroto-Rey
Giovanni Schinzari
Laurence Albiges

4576Background: TITAN-RCC uses a tailored immunotherapy approach in renal cell carcinoma (RCC), starting with nivolumab (nivo) induction followed by nivo + ipilimumab (ipi) as immunotherapeutic “bo...

Keywords:

Renal cell carcinoma
Ipilimumab
in patient
Immunotherapy
Oncology
Nivolumab
Medicine
Internal medicine
tailored approach

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations